109 related articles for article (PubMed ID: 6447707)
1. Potency of the effect of D-stereoisomer of aminoglutethimide on adrenal and extraadrenal steroidogenesis.
Samojlik E; Santen RJ
J Clin Endocrinol Metab; 1980 Sep; 51(3):462-5. PubMed ID: 6447707
[No Abstract] [Full Text] [Related]
2. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
Samojlik E; Santen RJ; Wells SA
J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399
[No Abstract] [Full Text] [Related]
3. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; Smith IE
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
[TBL] [Abstract][Full Text] [Related]
4. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
[TBL] [Abstract][Full Text] [Related]
5. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
6. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
Dowsett M; Harris AL; Smith IE; Jeffcoate SL
J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
[TBL] [Abstract][Full Text] [Related]
8. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Santen RJ; Samojlik E; Lipton A; Harvey H; Ruby EB; Wells SA; Kendall J
Cancer; 1977 Jun; 39(6 Suppl):2948-58. PubMed ID: 194681
[TBL] [Abstract][Full Text] [Related]
9. Endocrine treatment of breast cancer: effects upon intratumoral estrone sulfate metabolism and peripheral steroid levels.
Carlström K; Pousette A; Rannevik G; Sköldefors H; Theve NO; Wilking N
Breast Cancer Res Treat; 1986; 7 Suppl():S107-9. PubMed ID: 2943337
[No Abstract] [Full Text] [Related]
10. Aminoglutethimide in the treatment of advanced breast cancer.
Stuart-Harris RC; Smith IE
Cancer Treat Rev; 1984 Sep; 11(3):189-204. PubMed ID: 6241038
[No Abstract] [Full Text] [Related]
11. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate S
Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
[TBL] [Abstract][Full Text] [Related]
12. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
Samojlik E; Santen RJ
J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
[TBL] [Abstract][Full Text] [Related]
13. Medical adrenalectomy and plasma steroids in advanced breast carcinoma.
Newsome HH; Brown PW; Terz JJ; Lawrence W
Surgery; 1978 Jan; 83(1):83-9. PubMed ID: 619476
[TBL] [Abstract][Full Text] [Related]
14. How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
Worgul TJ; Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336
[TBL] [Abstract][Full Text] [Related]
15. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Samojlik E; Santen RJ; Kirschner MA; Ertel NH
Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
[TBL] [Abstract][Full Text] [Related]
16. Low-dose aminoglutethimide in treatment of advanced breast cancer.
Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE
Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642
[TBL] [Abstract][Full Text] [Related]
17. Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone.
Santen RJ; Wells SA; Runić S; Gupta C; Kendall J; Rudy EB; Samojlik E
J Clin Endocrinol Metab; 1977 Sep; 45(3):469-79. PubMed ID: 198423
[No Abstract] [Full Text] [Related]
18. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
[TBL] [Abstract][Full Text] [Related]
19. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501
[TBL] [Abstract][Full Text] [Related]
20. Cigarette smoking and levels of adrenal androgens in postmenopausal women.
Khaw KT; Tazuke S; Barrett-Connor E
N Engl J Med; 1988 Jun; 318(26):1705-9. PubMed ID: 2967432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]